drugset

drugset / Trial / NCT00168922

Study to Determine the Efficacy of Bendamustin in Patients With Recurrent Small Cell Lung Cancer (SCLC)

NCT00168922 ↗

Phase 2 Unknown 50 enrolled Charite University, Berlin, Germany ribosepharm GmbH · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

Determination of response rate Assessment of toxicity and determination of "time to progression"

Timeline

Start: 2001-02
Primary completion: —
Completion: 2006-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bendamustin	Unknown	—	—

Indications